Monthly Archives: November 2024

LPCs and Community Pharmacy England met with a range of advocates and patient groups last week to reflect on the outlook for the sector a year on from the publication of the Vision for Community Pharmacy. The Annual Conference of LPCs and Community Pharmacy England held last Thursday focussed on crucial considerations for the coming year, [...]

The post One Year on from Vision: LPCs and wider stakeholders consider the outlook for pharmacy appeared first on Community Pharmacy England.

NHS England will be relaunching their Pharmacy First public-facing campaign on Monday 11th October 2024. Minor revisions have been made to the original campaign materials used earlier this year, including additional information on the age criteria for the clinical pathways. Ahead of the official launch, the campaign materials are available on the Department of Health [...]

The post NHS England Pharmacy First campaign to re-start on Monday appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has confirmed that sufficient stock of Nyzamac® SR 60mg capsules is now available to meet normal demand. As a result the Serious Shortage Protocol (SSP), SSP076 Nyzamac® SR 60mg capsules expires at 23.59pm on Friday 8 November 2024. After this date, any prescriptions for Nyzamac® SR 60mg [...]

The post Expiry of SSP076 Nyzamac® SR 60mg capsules appeared first on Community Pharmacy England.

The Government has made The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (Extension) (No. 2) Order 2024, which has the effect of extending the ban, which was due to expire. The ban has been extended until 31 December 2024. The Secretary of State has expressed the intention to make the ban permanent, but can only do [...]

The post Legislation restricting the sale and supply of gonadotrophin-releasing hormone analogues further extended appeared first on Community Pharmacy England.

Class 4 Medicines Defect Information: Zoledronic Acid Ennogen 4mg/5ml concentrate for solution for infusion (Ennogen Healthcare Limited) Drug alert number: EL (24)A/53 Date issued: 07 November 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Zoledronic Acid Ennogen 4mg/5ml concentrate for solution for infusion (Ennogen [...]

The post MHRA Class 4 Medicines Defect Information: Zoledronic Acid Ennogen 4mg/5ml concentrate for solution for infusion (Ennogen Healthcare Limited) appeared first on Community Pharmacy England.